234 related articles for article (PubMed ID: 24502341)
1. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.
Chowdhury MY; Seo SK; Moon HJ; Talactac MR; Kim JH; Park ME; Son HY; Lee JS; Kim CJ
Virol J; 2014 Feb; 11():21. PubMed ID: 24502341
[TBL] [Abstract][Full Text] [Related]
2. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
3. Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice.
Kim EH; Lee JH; Pascua PN; Song MS; Baek YH; Kwon HI; Park SJ; Lim GJ; Decano A; Chowdhury MY; Seo SK; Song MK; Kim CJ; Choi YK
Virol J; 2013 Apr; 10():104. PubMed ID: 23551908
[TBL] [Abstract][Full Text] [Related]
4. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
[TBL] [Abstract][Full Text] [Related]
5. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.
Chang H; Huang C; Wu J; Fang F; Zhang W; Wang F; Chen Z
Virol J; 2010 Aug; 7():197. PubMed ID: 20727202
[TBL] [Abstract][Full Text] [Related]
6. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
7. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
8. Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
Kim KH; Jung YJ; Lee Y; Park BR; Oh J; Lee YN; Kim MC; Jeeva S; Kang SM
Virology; 2020 Nov; 550():51-60. PubMed ID: 32882637
[TBL] [Abstract][Full Text] [Related]
9. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
10. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.
Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS
Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616
[TBL] [Abstract][Full Text] [Related]
11. Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes.
Li R; Chowdhury MY; Kim JH; Kim TH; Pathinayake P; Koo WS; Park ME; Yoon JE; Roh JB; Hong SP; Sung MH; Lee JS; Kim CJ
Vet Microbiol; 2015 Sep; 179(3-4):250-63. PubMed ID: 26210951
[TBL] [Abstract][Full Text] [Related]
12. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
13. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
14. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
[TBL] [Abstract][Full Text] [Related]
15. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
[TBL] [Abstract][Full Text] [Related]
16. Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
Kim J; Chang J
Vaccine; 2024 May; 42(15):3505-3513. PubMed ID: 38714444
[TBL] [Abstract][Full Text] [Related]
17. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
Tompkins SM; Zhao ZS; Lo CY; Misplon JA; Liu T; Ye Z; Hogan RJ; Wu Z; Benton KA; Tumpey TM; Epstein SL
Emerg Infect Dis; 2007 Mar; 13(3):426-35. PubMed ID: 17552096
[TBL] [Abstract][Full Text] [Related]
18. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
19. Immune responses of mice inoculated with recombinant Lactobacillus plantarum NC8 expressing the fusion gene HA2 and 3M2e of the influenza virus and protection against different subtypes of influenza virus.
Bo F; Yang WT; Shonyela SM; Jin YB; Huang KY; Shao LN; Wang C; Zhou Y; Li QY; Jiang YL; Huang HB; Shi CW; Wang JZ; Wang G; Kang YH; Yang GL; Wang CF
Virus Res; 2019 Apr; 263():64-72. PubMed ID: 30611823
[TBL] [Abstract][Full Text] [Related]
20. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene.
Kamlangdee A; Kingstad-Bakke B; Anderson TK; Goldberg TL; Osorio JE
J Virol; 2014 Nov; 88(22):13300-9. PubMed ID: 25210173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
